tetano
Editor, Senior Moderator
Transpl Immunol
. 2022 Apr 4;101599.
doi: 10.1016/j.trim.2022.101599. Online ahead of print.
Serologic response to a third dose of an mRNA-based SARS-CoV-2 vaccine in lung transplant recipients
T W Hoffman[SUP] 1 [/SUP], B Meek[SUP] 2 [/SUP], G T Rijkers[SUP] 3 [/SUP], D A van Kessel[SUP] 4 [/SUP]
Affiliations
Abstract
Lung transplant recipients have an increased risk for severe coronavirus disease 2019 (COVID-19) due to infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A third dose of a SARS-CoV-2 vaccine has been recommended for all solid organ transplant recipients, but data from lung transplant recipients specifically are scarce. In this study, the serologic response to a third dose of an mRNA-based SARS-CoV-2 vaccine was measured in 78 lung transplant recipients. Sixty-two percent (n = 48) had a serological response to vaccination, which was significantly higher than after the second vaccine dose (27 patients (35%); p = 0.0013). A positive serologic response was associated with having had COVID-19 (p = 0.01), and higher serum IgG level and complement mannose binding lectin pathway activity prior to vaccination (p = 0.04 and p = 0.03, respectively). Serologic response was not associated with the dose of mycophenolate mofetil or prednisone or other immune status parameters. Eleven patients (14%) developed COVID-19 after the second or third vaccine dose, but this did not associate with serologic response after the second vaccine dose (9% in patients who developed COVID-19 versus 39% in patients who did not develop 6.81; interquartile range 6.12-8.39), or with serologic response above cut-off values associated with clinical protection in previous studies. In conclusion, the response to mRNA-based SARS-CoV-2 vaccines in lung transplant recipients improves significantly after a third vaccine dose. Factors associated with a positive serologic response are having had COVID-19 prior to vaccination, and serum IgG and complement mannose binding lectin pathway activity prior to vaccination. Serologic response did not associate with clinical protection against COVID-19 in this study.
Keywords: COVID-19; Lung transplant; SARS-CoV-2; Vaccination response.
. 2022 Apr 4;101599.
doi: 10.1016/j.trim.2022.101599. Online ahead of print.
Serologic response to a third dose of an mRNA-based SARS-CoV-2 vaccine in lung transplant recipients
T W Hoffman[SUP] 1 [/SUP], B Meek[SUP] 2 [/SUP], G T Rijkers[SUP] 3 [/SUP], D A van Kessel[SUP] 4 [/SUP]
Affiliations
- PMID: 35390480
- DOI: 10.1016/j.trim.2022.101599
Abstract
Lung transplant recipients have an increased risk for severe coronavirus disease 2019 (COVID-19) due to infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A third dose of a SARS-CoV-2 vaccine has been recommended for all solid organ transplant recipients, but data from lung transplant recipients specifically are scarce. In this study, the serologic response to a third dose of an mRNA-based SARS-CoV-2 vaccine was measured in 78 lung transplant recipients. Sixty-two percent (n = 48) had a serological response to vaccination, which was significantly higher than after the second vaccine dose (27 patients (35%); p = 0.0013). A positive serologic response was associated with having had COVID-19 (p = 0.01), and higher serum IgG level and complement mannose binding lectin pathway activity prior to vaccination (p = 0.04 and p = 0.03, respectively). Serologic response was not associated with the dose of mycophenolate mofetil or prednisone or other immune status parameters. Eleven patients (14%) developed COVID-19 after the second or third vaccine dose, but this did not associate with serologic response after the second vaccine dose (9% in patients who developed COVID-19 versus 39% in patients who did not develop 6.81; interquartile range 6.12-8.39), or with serologic response above cut-off values associated with clinical protection in previous studies. In conclusion, the response to mRNA-based SARS-CoV-2 vaccines in lung transplant recipients improves significantly after a third vaccine dose. Factors associated with a positive serologic response are having had COVID-19 prior to vaccination, and serum IgG and complement mannose binding lectin pathway activity prior to vaccination. Serologic response did not associate with clinical protection against COVID-19 in this study.
Keywords: COVID-19; Lung transplant; SARS-CoV-2; Vaccination response.